Condition: COVID -19 · COVID-19 (Prevention) · Sponsor: ModeX Therapeutics, An OPKO Health Company
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo.
This description comes directly from the study's public registry record.
ModeX Therapeutics, An OPKO Health Company · 857-233-9936 · info@modextx.com
Always discuss trial participation with your own doctor first.
| TrialMed Clinical Research Unit | Las Vegas, Nevada, United States | Recruiting |
| TrialMed Clinical Research Unit | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07445971